(Fighting against New Coronary Pneumonia) China's National Health Commission: The domestically-made new crown vaccine is safe and will be ordered
China News Service, Beijing, December 31 (Li Jingze) Zeng Yixin, deputy director of the National Health Commission of China and head of the vaccine research team of the Joint Prevention and Control Mechanism of the State Council, said in Beijing on December 31 that the Chinese new crown vaccine is safe. Vaccination will be carried out in an orderly manner.
On the same day, the Joint Prevention and Control Mechanism of the State Council of China held a press conference on the conditional listing of the new coronavirus vaccine and related work.
Zeng Yixin said at the meeting that in order to protect high-risk groups, in June of this year, in accordance with the "New Coronavirus Vaccine Emergency Use Plan" approved by law and regulations, China adopted the principles of small-scale start, prudent and informed consent, and the Under the premise of response monitoring and emergency treatment preparations, emergency vaccination of new crown vaccines will be carried out for high-risk groups.
By the end of November, a total of more than 1.5 million doses had been vaccinated, and about 60,000 of them had gone to work in high-risk areas overseas. There were no reports of serious infections. The safety of the vaccine has been fully proven, and its effectiveness has been verified to some extent.
On this basis, in order to prevent the outbreak of the epidemic in winter and spring, China officially launched the vaccination of key populations on December 15.
In the past two months, the cumulative vaccination of key populations across the country has exceeded 3 million doses.
"This 3 million, plus the previous 1.5 million, fully proves that China's vaccine is safe." Zeng Yixin said.
"Of course, a certain proportion of adverse reactions occurred. The total incidence is very close to those of the inactivated vaccines routinely vaccinated. The main manifestations are some local pain and local induration." Zeng Yixin said that the number of mild fever cases is probably less than 0.1 %, the incidence of more serious adverse reactions such as allergic reactions is about two per million; these conditions have been treated in time and have been well treated.
Zeng Yixin revealed that in the next step, with the approval of the vaccine’s conditional listing, China will comprehensively and orderly promote the vaccination of the elderly and high-risk groups with underlying diseases, and follow up with other general population vaccination.
At present, the Expert Advisory Committee of China's Immunization Program has formulated a unified vaccination plan, and vaccination will be carried out in an orderly manner, so that all eligible people can realize the “sufficiency” and gradually build an immune barrier for the entire population to block the spread of the new crown virus. The new crown pneumonia epidemic can be thoroughly controlled.
He said that China's vaccine research and development work has always been the world's first phalanx.
"In the process of vaccine development and production, we always put the safety and effectiveness of vaccines first."
Zheng Zhongwei, head of the Vaccine R&D Special Team of the Joint Prevention and Control Mechanism Research Team of the State Council of China, and director of the National Health Commission’s Medical and Health Technology Development Research Center, also emphasized at the meeting that the vaccine development process is a race against the virus, but China fully respects vaccines Scientific laws and scientific principles of research and development. China is the first to carry out clinical trials and also the first to carry out phase III clinical trials. However, due to the good control of the epidemic situation in China, China conducts clinical trials abroad, strictly abides by relevant rules during the clinical trial process, and will never "run away" for first place. (Finish)